shape-element-one
shape-element-two

TAADNext®

Thoracic aortic aneurysms and dissections, Marfan syndrome, and other related disorders are serious genetic conditions that often contribute to sudden cardiac death, so an accurate diagnosis is essential to prevent life-threatening events. TAADNext precisely analyzes 35 genes associated with these disorders, helping you confirm a diagnosis that aids in patient management and treatment options.

TAAD Syndrome Genetic Testing | TAADNext

Thoracic aortic aneurysms and dissections, Marfan syndrome, and other related disorders are serious genetic conditions that often contribute to sudden cardiac death, so an accurate diagnosis is essential to prevent life-threatening events. TAADNext precisely analyzes 35 genes associated with these disorders, helping you confirm a diagnosis that aids in patient management and treatment options.

TAADNext is a comprehensive analysis of 35 genes associated with TAAD and related disorders. Genomic deoxyribonucleic acid (gDNA) is isolated from the patient’s specimen using a standardized kit and quantified. Sequence enrichment of the targeted coding exons and adjacent intronic nucleotides is carried out by a bait-capture methodology using long biotinylated oligonucleotide probes, and is followed by polymerase chain reaction (PCR) and Next-Generation sequencing. Additional Sanger sequencing is performed for any regions missing or with insufficient read depth coverage for reliable heterozygous variant detection. Potentially homozygous variants, variants in regions complicated by pseudogene interference, and variant calls not satisfying depth of coverage and variant allele frequency quality thresholds are verified by Sanger sequencing. This assay targets all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. Gross deletion/duplication analysis is performed for all genes (excluding CBS and TNXB exons 32-44) using a custom pipeline based on read-depth from NGS data followed by a confirmatory orthogonal method, as needed. Exon-level resolution may not be achieved for every gene.

1. Korkko J, et al. Sensitivity of conformation sensitive gel electrophoresis in detecting mutations in Marfan syndrome and related conditions. J Med Genet. 2002;39:34–41.

2. Pepin MG and Byers PH. Ehlers-Danlos Syndrome Type IV. 1999 Sep 2 [Updated 2011 May 3]. In: Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.

3. Milewicz DM and Regalado E. Thoracic Aortic Aneurysms and Aortic Dissections. 2003 Feb 13 Updated 2012 Jan 12. In: Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.

Genes analyzed
Code
Test Name
Turnaround
Genes
8783
FBN1 reflex to TAADNext
14-21 days
35 Genes
8789
TAADNext®
14-21 days
35 Genes
FBN1 reflex to TAADNext
35 Genes
ACTA2
BGN
CBS
CHST14
COL1A1
COL1A2
COL3A1
COL5A1
COL5A2
EFEMP2
FBN1
FBN2
FKBP14
FLNA
FOXE3
LOX
MAT2A
MED12
MFAP5
MYH11
MYLK
NOTCH1
PLOD1
PRDM5
PRKG1
SKI
SLC2A10
SMAD3
SMAD4
TGFB2
TGFB3
TGFBR1
TGFBR2
TNXB
ZNF469
TAADNext®
35 Genes
ACTA2
BGN
CBS
CHST14
COL1A1
COL1A2
COL3A1
COL5A1
COL5A2
EFEMP2
FBN1
FBN2
FKBP14
FLNA
FOXE3
LOX
MAT2A
MED12
MFAP5
MYH11
MYLK
NOTCH1
PLOD1
PRDM5
PRKG1
SKI
SLC2A10
SMAD3
SMAD4
TGFB2
TGFB3
TGFBR1
TGFBR2
TNXB
ZNF469
Test Requisition Form
Private: Cardiovascular
Consent
Private: Cardiovascular Genetics
Clinician Management Resources + Understanding Your Results
Negative Thoracic Aortic Aneurysms/Dissections (TAAD)
Positive Thoracic Aortic Aneurysms/Dissections (TAAD)
VUS Thoracic Aortic Aneurysms/Dissections (TAAD)
White Papers and Case Studies
Private: Cardiomyopathy and Arrhythmia Panels Cardiology
Why genetic testing matters

Knowing if your patient has a hereditary cardiovascular disorder can help you determine their future cardiovascular disease risks and guide your medical management recommendations. Key benefits include:

  • Clarify diagnosis and risk for aortic aneurysms/dissection
  • Target medical management and prevention of aortic aneurysms/dissection and other complications
  • Offer family members genetic testing (for a familial mutation) and implement medical surveillance to only those that need it
  • Reduce healthcare costs, resources, and anxiety for families
When To Consider Testing

Patient is clinically suspected to have MFS, Marfan syndrome-related disorders, or familial TAAD For differential diagnosis and carrier testing of individuals with a family history, but no concrete diagnosis

Mutation Distribution and Detection Rates
Up to 93%
Marfan syndrome
of patients have a mutation in the FBN1 gene**
**Korkko et al., J Med Genet 2002
>95%
EDS type IV
of patients mutation in the COL3A1 gene**
**Pepin & Byers, GeneReviews 2011
30-40%
familial TAAD
of patients have a mutation in one of the TAADNext genes**
**Milewicz & Regalado, GeneReviews 2012

Test Description

TAADNext is a comprehensive analysis of 35 genes associated with TAAD and related disorders. Genomic deoxyribonucleic acid (gDNA) is isolated from the patient’s specimen using a standardized kit and quantified. Sequence enrichment of the targeted coding exons and adjacent intronic nucleotides is carried out by a bait-capture methodology using long biotinylated oligonucleotide probes, and is followed by polymerase chain reaction (PCR) and Next-Generation sequencing. Additional Sanger sequencing is performed for any regions missing or with insufficient read depth coverage for reliable heterozygous variant detection. Potentially homozygous variants, variants in regions complicated by pseudogene interference, and variant calls not satisfying depth of coverage and variant allele frequency quality thresholds are verified by Sanger sequencing. This assay targets all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. Gross deletion/duplication analysis is performed using a custom pipeline based on read-depth from NGS data followed by a confirmatory orthogonal method, as needed. Exon-level resolution may not be achieved for every gene.

1. Korkko J, et al. Sensitivity of conformation sensitive gel electrophoresis in detecting mutations in Marfan syndrome and related conditions. J Med Genet. 2002;39:34–41.

2. Pepin MG and Byers PH. Ehlers-Danlos Syndrome Type IV. 1999 Sep 2 [Updated 2011 May 3]. In: Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.

3. Milewicz DM and Regalado E. Thoracic Aortic Aneurysms and Aortic Dissections. 2003 Feb 13 Updated 2012 Jan 12. In: Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.